Growth Metrics

Tandem Diabetes Care (TNDM) Common Equity (2016 - 2026)

Tandem Diabetes Care filings provide 13 years of Common Equity readings, the most recent being $155.2 million for Q4 2025.

  • On a quarterly basis, Common Equity fell 41.02% to $155.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $155.2 million, a 41.02% decrease, with the full-year FY2025 number at $155.2 million, down 41.02% from a year prior.
  • Common Equity hit $155.2 million in Q4 2025 for Tandem Diabetes Care, up from $133.0 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $449.6 million in Q2 2022 to a low of $133.0 million in Q3 2025.
  • Median Common Equity over the past 5 years was $313.8 million (2023), compared with a mean of $304.1 million.
  • Biggest five-year swings in Common Equity: soared 51.28% in 2021 and later crashed 44.06% in 2025.
  • Tandem Diabetes Care's Common Equity stood at $433.1 million in 2021, then rose by 1.58% to $439.9 million in 2022, then decreased by 28.71% to $313.6 million in 2023, then dropped by 16.11% to $263.1 million in 2024, then tumbled by 41.02% to $155.2 million in 2025.
  • The last three reported values for Common Equity were $155.2 million (Q4 2025), $133.0 million (Q3 2025), and $133.3 million (Q2 2025) per Business Quant data.